Question explored with the scientific record
I sped sratins was that a good idea
Yes to statins for someone with established heart disease. For a healthy person with no heart disease, the benefit is small and the decision is genuinely close.
The decision turns on who you are. If you already have heart disease, or a recent heart attack or stroke, the evidence for statins is strong and uses hard outcomes. Simvastatin cut major events by a third in people with established coronary disease [2]. High-intensity statins after acute coronary syndrome beat standard statins [2]. Patients with acute cardioembolic stroke given statins had far fewer major vascular events and deaths, though that was an observational study, not randomized [3]. That is real proof in high-risk people.
For primary prevention, the honest picture is murkier. The overall benefit shrinks to about a 1.5% five-year reduction in major vascular events [6]. Which means many people treated, one event avoided. Whether that trade is worth it depends on your actual risk, and the risk calculators themselves disagree. The PREVENT equation estimates much lower risk than the older PCE, and if it were adopted, roughly 14.3 million adults who qualify under PCE would no longer qualify [1]. No one agrees who should take this.
Here is who was studied and what they found:
| Population | Effect | Source |
|---|---|---|
| Established heart disease | ~30% fewer major events | [2] |
| Primary prevention (average) | ~1.5% fewer events over 5 years | [6] |
| LDL cut of 30-50% | More diabetes; 18% with intensive lowering | [5] |
| Statin users reporting muscle pain | ~90% of symptom burden triggered by placebo in one trial | [9] |
The muscle side effects are real, but often the nocebo effect. In a randomized placebo-controlled series in people who had quit statins for muscle pain, symptoms during statin and placebo months were about the same [4][7]. That does not mean every complaint is imaginary. Statin-induced autoimmune myopathy is a documented, severe exception [8][10], and claims of "it's all nocebo" are refuted by that. If you have real weakness or dark urine, stop and get tested.
Who paid for this evidence base matters, and this retrieval does not tell you. Many statin trials are manufacturer-run, and the most informative comparison, treated versus genuinely untreated for decades, was never run.
My call: if you have diagnosed heart disease, staying on statins is a good decision. If you are healthy with no heart disease, and especially if your 10-year risk is under 7.5%, the honest answer is that the numbers favor statins less than you were told. Ask for your actual risk estimate under both PREVENT and PCE, and decide from that.
Confidence: moderate for secondary prevention, low for primary prevention in healthy people.
Sources used 10
-
The Role of Risk Equations in Primary Prevention of Atherosclerotic Cardiovascular Disease
This narrative review concludes that PREVENT improves cardiovascular risk prediction versus PCE but its lower risk estimates and reduced statin eligibility raise undertreatment concerns.
DOI: 10.53941/ijctm.2025.100003 -
An Overview of the Impact of Statin Therapy on Cardiac Incident Risk
This narrative review summarizes evidence that statin therapy lowers LDL cholesterol and reduces major cardiovascular events in primary and secondary prevention, while noting muscle symptoms and a modest increased risk of type 2 diabetes as adverse effects.
DOI: 10.12775/qs.2025.38.58289 -
Statin therapy in acute cardioembolic stroke with no guidance-based indication
Starting statin therapy during hospitalization for acute cardioembolic stroke in patients without guideline-based statin indications significantly reduced major vascular events (adjusted HR 0.39, 95% CI 0.31–0.48), vascular death (HR 0.28, 0.21–0.36), and all-cause death (HR 0.5…
DOI: 10.1212/wnl.0000000000009397 -
Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
This narrative review synthesizes evidence that statin-associated muscle symptoms are largely attributable to the nocebo effect and are frequently manageable with individualized rechallenge and dosing strategies.
DOI: 10.1002/phar.2681 -
Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis
In a meta-analysis of 14 statin trials, greater LDL-c reduction was associated with increased risk of new-onset diabetes; risks were elevated with reductions of 30-50%, while reductions below 30% did not significantly increase risk.
DOI: 10.1038/srep39982 -
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
This systematic review and meta-analysis evaluates the relationship between lowering low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk reduction across various therapeutic interventions, finding that both statins and nonstatin therapies that upregulate LDL rece…
DOI: 10.1001/jama.2016.13985 -
impact of the nocebo effect on discontinuation of statin therapy due to myopathy in patients with cardiovascular disease – a review
This narrative review synthesizes randomized and observational evidence that the nocebo effect substantially drives patient-reported muscle symptoms during statin therapy and that true statin-induced myopathy is rarer than patient reports suggest.
DOI: 10.12775/qs.2024.31.55769 -
Statin-induced necrotising autoimmune myopathy: a rare complication of statin therapy
A 52-year-old man on atorvastatin for 3 years developed statin-induced necrotising autoimmune myopathy (SINAM) with proximal weakness and CK >10,000 U/L, confirmed by positive anti-HMG-CoA reductase antibodies, MRI showing diffuse muscle oedema, and necrotising myopathy on biops…
DOI: 10.1136/bcr-2020-240865 -
Statin-induced muscle symptoms
Nocebo effects largely explain statin associated muscle symptoms, and individualized information and management enable most patients to resume or continue statin therapy with fewer or no adverse symptoms.
DOI: 10.61409/v03250169 -
Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy
Statin-induced necrotizing autoimmune myopathy is a rare, autoantibody-associated complication of statin therapy presenting with proximal muscle weakness that persists after statin withdrawal and responds to early immunosuppressive therapy.
DOI: 10.32756/0869-5490-2022-2-76-80